Edgar Filing: Atara Biotherapeutics, Inc. - Form 4

Atara Biother	apeutics, Inc.										
Form 4 February 11, 2	0016										
								OMB A	PPROVAL		
FORM	UNITEDS	TATES S			ND EXC D.C. 205		COMMISSION		3235-0287		
Check this if no longe	r	ENT OF (NEDSHIDAE	Expires:	January 31, 2005		
subject to Section 16 Form 4 or	ction 16. SECURITIES						NERSIII OF	Estimated average burden hours per response			
Form 5 obligations may contir <i>See</i> Instruct 1(b).	Section 17(a) of the Pu	ıblic Uti	lity Hold	ing Com	U U	e Act of 1934, f 1935 or Section 40		0.0		
(Print or Type Re	esponses)										
MCCDATHIOUN			2. Issuer Name and Ticker or Trading Symbol			5. Relationship of Reporting Person(s) to Issuer					
					ra Biotherapeutics, Inc. [ATRA]			(Check all applicable)			
			3. Date of Earliest Transaction (Month/Day/Year) 02/09/2016				Director 10% Owner X Officer (give title Other (specify below) below) Chief Financial Officer				
				Amendment, Date Original d(Month/Day/Year)			 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person 				
SOUTH SAN FRANCISCO							Form filed by M Person	Iore than One Ro	eporting		
(City)	(State) (2	Zip)	Table	I - Non-D	erivative S	ecurities Acq	uired, Disposed of	f, or Beneficial	lly Owned		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deeme Execution I any (Month/Day	Date, if	Code (Instr. 8)	4. Securiti on(A) or Dis (D) (Instr. 3, 4 Amount	posed of	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

А

Common

Stock

02/09/2016

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

D

\$0 79,213

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

42,857

(1)

А

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. 6. Date Exercisable and orNumber Expiration Date of (Month/Day/Year) Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		Date	Amou Under Secur	le and unt of rlying rities : 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owne Follo Repo Trans (Instr
Repo	rting O	wners		Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
MCGRATH JOHN 701 GATEWAY BOULEVARD SUITE 200 SOUTH SAN FRANCISCO, CA 94080			Chief Financial Officer				
Signatures							
/s/ Tina Gullotta, Attorney-in-Fact for Jo McGrath, Jr.	hn F.		02/11/2016				
**Signature of Reporting Person			Date				

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These restricted stock units vest in four equal annual installments on each of the first, second, third and fourth anniversaries of the grant date, subject to the reporting person's continuous service.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Edgar Filing: Atara Biotherapeutics, Inc. - Form 4